Collaborations

Companies form alliance to design, validate gene-marker panels

Published in Obesity and Diabetes Week, August 16th, 2004

Illumina, Inc., (ILMN), a provider of integrated solutions for the large-scale analysis of genetic variation and function, and Genomas, Inc., a healthcare company developing products for personalized treatments of obesity and related metabolic disorders, announced a collaboration for the design and validation of gene marker panels.

Under the agreement, Genomas will use the Illumina BeadStation 500GX for the discovery of diagnostic markers to be used in the development of PhysioTypes. PhysioTypes are predictors incorporating haplotypes from various genes, baseline physiological and clinical information, and demographic data. Genomas will develop PhysioTypes for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry